FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin HCl) from Janssen Pharmaceuticals, Inc. under NDA 205879.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)

Snippet

SUPPL AP for INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)